# OnCo record tacquell (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tacquell/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tacquell" ;
  schema:name "Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)"@en ;
  schema:alternateName "Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded"@en, "Tacquell" ;
  schema:description "Tacquell is a tumour-infiltrating lymphocyte therapy for melanoma developed by the Netherlands Cancer Institute, the academic group whose randomised trial first showed TIL therapy could beat ipilimumab. Europe's medicines committee gave it a negative opinion in June 2026, so it is not authorised."@en ;
  schema:url <https://onco.cc/drugs/tacquell/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/tacquell> ;
  onco:tag "ema-register" ;
  onco:modality "TIL cell therapy (autologous tumour-infiltrating lymphocytes, ex vivo expanded)" ;
  onco:related <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/til-therapy/> ;
  onco:institutions <https://onco.cc/institutions/nki/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/> .